References
- Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(1 Suppl):S6–9.
- Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438–50.
- Falconer K, Sandberg JK, Reichard O, Alaeus A. HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatment. Scand J Infect Dis 2009;41:881–5.
- Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, . Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 1993;177:1809–14.
- Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, . Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006;194:895–903.
- Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, . IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006;44:1617–25.
- Askarieh G, Alsio A, Pugnale P, Negro F, Ferrari C, Neumann AU, . Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010;51:1523–30.
- Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, Gangl A, . IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV–HCV coinfection. Antivir Ther 2008;13:969–76.
- Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 2007;45:262–8.
- Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, . Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282: 103–7.
- Cotler SJ, Layden JE, Neumann AU, Jensen DM. First phase hepatitis C viral kinetics in previous nonresponder patients. J Viral Hepat 2003;10:43–9.
- Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, Ruggiero G. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis 2009;49:498–506.
- Gonzalez VD, Falconer K, Michaelsson J, Moll M, Reichard O, Alaeus A, . Expansion of CD56-NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin Immunol 2008; 128:46–56.
- Gonzalez VD, Falconer K, Blom KG, Reichard O, Morn B, Laursen AL, . High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009;83: 11407–11.
- Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, . International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005;43:250–7.
- Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, . Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008;105:7034–9.